/ / / BUSINESS: Presentations Of Blue Light Flexible Cystoscopy Study Results And Bladder Cancer Surgical Techniques Featured At AUA 2021
| | |

BUSINESS: Presentations Of Blue Light Flexible Cystoscopy Study Results And Bladder Cancer Surgical Techniques Featured At AUA 2021

By Daniel Webster, dWeb.News Publisher

OSLO, Norway, Sept. 15, 2021 /PRNewswire/ — Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces a clinical data presentation and highlights from the 2021 American Urological Association Annual Congress (AUA2021), which was held virtually September 10-13, 2021. During the program, new results from a study using Blue Light Cystoscopy (BLC(r)) with Cysview(r) in the surveillance setting were reported in a podium presentation, and separately, BLC with Cysview was discussed in an Expert Presentation on Surgical Techniques.

The American Urological Association (AUA) meeting is one of largest international meetings in the urology calendar. The AUA meeting featured an innovative, evidence-based, high quality program for urologists worldwide.

Podium Presentation


Presenter: Sanam Ladi Seyedian, M.D., University of Southern California

Session and Date: PD-63: Bladder: Cancer Non-Invasive III: Sept. 13, 2021

Results were provided by two high-volume treatment facilities that perform Blue Light Flexible Cystoscopy (BLFC) and are participants in the Blue Light Cystoscopy with Cysview Registry. In this study, data was captured from 277 office based BLFC examinations in 136 patients who received intravesical BCG or chemotherapy, as part of standard of care treatment for non-muscle invasive bladder cancer (NMIBC).

From these examinations, a total of 52 office-based biopsies were taken, of which 23 (44%) were confirmed as malignant. BLFC identified all 23 malignancies, demonstrating 100% sensitivity for cancer detection in this cohort, whereas analysis by cytology identified only 3 of the 23 confirmed malignancies. Additionally, from the 277 total examinations, 23 (8%) were White Light Cystoscopy (WLC) normal and BLFC abnormal. Of these 23 discordant results, 16 had office-based biopsies and cancer was confirmed in 9 cases (56%), which would have been missed by WLC alone. The study authors concluded that office-based Blue Light Cystoscopy with Cysview helps to detect recurrence early in patients who have received intravesical therapy. They also improve the performance of office-based biopsies and help in early detection of unresponsive BCG.

“The results from this study show that use of Blue Light Cystoscopy with Cysview for patient surveillance improved the ability to detect recurrent disease in this high-risk, recently-treated patient cohort, which can significantly impact future treatment decisions,” said Dr. Sia Daneshmand, one of the study authors. “Blue Light Cystoscopy can be an important tool throughout the continuum of care for patients diagnosed with bladder cancer.” As a result, Blue Light Cystoscopy can be an important tool throughout the continuum of care for patients diagnosed with bladder cancer.”

Dr. Sia Daneshmand, M.D., is a Professor of Urology with Clinical Scholar designation and serves as director of clinical research as well as the urologic oncology (SUO) fellowship director at the University of Southern California (USC) in Los Angeles.

Abstract Link: 03

Expert Presentation


Presenter: Yair Lotan, M.D., UT Southwestern Medical Center

Session and Date: Plenary Session: Surgical Techniques: Sept. 10, 2021

In this presentation, Dr. Lotan emphasized the importance of BLC with Cysview in accurately detecting NMIBC, stratifying bladder tumors, and helping to perform a complete TURBT in the operating room. Dr. Lotan also shared his expert opinion on how biopsy and fulguration can positively impact patient outcomes when using Cysview in an office setting.

Dr. Lotan holds the position of Professor at UT Southwestern and Jane and John Justin Distinguished chair in Urology, In Honour of Claus G. Roehrborn , Dr. Lotan. He is vice chair of Clinical Affairs, chief of urologiconcology and chief of clinical affairs.

“The study results presented at this year’s AUA meeting as well as the discussion on BLC in the Surgical Techniques presentation underscores how critically important it is for patients to receive the proper bladder cancer care whether they are having tumor resection in the hospital or follow-up procedures” said Geoffrey Coy, Vice President and General Manager of North American Operations at Photocure. These new results highlight the many opportunities Blue Light Cystoscopy offers for urologists and the benefits that patients receive, particularly when it is included in the continuum care. We will continue to expand the availability of this procedure so that more doctors and patients can access it.

Note to editors: All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA

About Bladder Cancer

Bladder cancer ranks as the seventh most common cancer worldwide with 1 720 000 prevalent cases (5-year prevalence rate)1a, 573 000 new cases and more than 200 000 deaths annually in 2020. 1b

Approx. 75% of all bladder cancer cases occur in men. 1 It has a high recurrence rate with an average of 61% in year one and 78% over five years. 2 Bladder cancer has the highest lifetime treatment costs per patient of all cancers. 3

Bladder cancer is a costly, potentially progressive disease for which patients have to undergo multiple cystoscopies due to the high risk of recurrence. Patients and healthcare professionals alike need to be able to better diagnose and manage bladder cancer.

Bladder cancer can be divided into two types: non-muscle-invasive bladder carcinoma (NMIBC), and muscle-invasive bladder carcinoma (MIBC), according to the extent of bladder wall invasion. NMIBC is found in the inner bladder cells. These cancers are the most common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. MIBC is characterized by cancer that has spread to deeper layers of bladder wall. These cancers, which include subtypes T2, T3, T4, and T5, are more likely to spread than others and are difficult to treat. 4

1 Globocan. A) 5-year prevalence/b) incidence/mortality according to population.

Available at:, accessed [April 2021].

2 Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657

3 Sievert KD et al. World J Urol 2009;27: 295-300

4 Bladder Cancer. American Cancer Society.

About Hexvix(r)/Cysview(r) (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the bladder making them glow bright pink during Blue Light Cystoscopy (BLC(r)). BLC with Hexvix/Cysview increases the detection of tumors, leads to better management decisions and a more complete resection.

Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all other markets. Photocure is commercializing Cysview/Hexvix directly in the U.S. and Europe and has strategic partnerships for the commercialization of Hexvix/Cysview in China, Canada, Chile, Australia, and New Zealand. Please refer to for further information on our commercial partners.

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Patients around the world have seen better outcomes due to our unique technology that makes cancer cells glow bright pink. Photocure is based in Oslo (Norway ) and is listed on the Oslo Stock Exchange. Visit and for more information.

For further information, please contact:

Dan Schneider

President and CEO

Photocure ASA

Email: d[email protected]

Erik Dahl


Photocure ASA

Tel: +4745055000

Email: [email protected]

David Moskowitz

Head of Investor Relations

Tel: +1 202 280 0888

Email: [email protected]

Media and IR enquiries:

Geir Bjorlo

Corporate Communications (Norway)

Tel: +47 91540000

Email: [email protected]

This information was brought to you by Cision,c3414940

The following files are available for download:

SOURCE Photocure

For more dWeb.News Business News:

Similar Posts

Leave a Reply